Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.

ABSTRACT:

Background

In 2009, the Global Fund to Fight AIDS, Tuberculosis and Malaria established the Affordable Medicines Facility-malaria (AMFm) in order to increase access to quality-assured artemisinin combination therapy (QAACT). AMFm Phase 1, which includes nine pilot programmes in eight countries, was launched in 2009. The objective of this study was to assess anti-malarial stock and purchase patterns at private outlets in five AMFm Phase 1 countries in regard to three of the core AMFm goals: increase the affordability of QAACT, increase the availability of QAACT, and crowd out artemisinin monotherapies and other substandard therapies.

Methods

The study was conducted between April and May 2012 and included interviews with personnel in 598 private pharmaceutical outlets in Ghana

SUBMITTER: Davis B 

PROVIDER: S-EPMC3637826 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature